9,10-Dioxoanthracenyldithiocarbamates effectively inhibit the proliferation of non-small cell lung cancer by targeting multiple protein tyrosine kinases

References

• Thandra KC, Barsouk A, Saginala K, Aluru JS, Barsouk A. Epidemiology of lung cancer. Contemp. Oncol. 2021;25(1):45.
   Google Scholar
• Siddamurthi S, Gutti G, Jana S, Kumar A, Singh SK. Anthraquinone: a promising scaffold for the discovery and development of therapeutic agents in cancer therapy. Future Med Chem. 2020;12(11):1037–1069.
   PubMed Web of Science ®Google Scholar
• Gaya E, Fernández-Brime S, Vargas R, Lachlan RF, Gueidan C, Ramírez-Mejía M, Lutzoni F. The adaptive radiation of lichen-forming Teloschistaceae is associated with sunscreening pigments and a bark-to-rock substrate shift. Proc Natl Acad Sci U S A. 2015;112(37):11600–11605.
   PubMed Web of Science ®Google Scholar
• Kim HS, Lee YS, Kim DK. Doxorubicin exerts cytotoxic effects through cell cycle arrest and Fas-mediated cell death. Pharmacology. 2009;84(5):300–309.
   PubMed Web of Science ®Google Scholar
• Tian W, Li J, Su Z, Lan F, Li Z, Liang D, Wang C, Li D, Hou H. Novel anthraquinone compounds induce cancer cell death through paraptosis. ACS Med Chem Lett. 2019;10(5):732–736.
   PubMed Web of Science ®Google Scholar
• Park SH, Lee J, Kang MA, Jang KY, Kim JR. Mitoxantrone induces apoptosis in osteosarcoma cells through regulation of the Akt/FOXO3 pathway. Oncol. Lett. 2018;15(6):9687.
   PubMed Web of Science ®Google Scholar
• Levitzki A. Tyrosine kinases as targets for cancer therapy. Eur J Cancer. 2002;38 Suppl 5:S11–S18.
   PubMedGoogle Scholar
• Lyu YL, Kerrigan JE, Lin CP, Azarova AM, Tsai YC, Ban Y, Liu LF. Topoisomerase Iiβ–mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res. 2007;67(18):8839–8846.
   PubMed Web of Science ®Google Scholar
• Ren L, Li Z, Dai C, Zhao D, Wang Y, Ma C, et al. Chrysophanol inhibits proliferation and induces apoptosis through NF-κB/cyclin D1 and NF-κB/Bcl-2 signaling cascade in breast cancer cell lines. Mol. Med. Rep. 2018;17(3):4376–4382.
   PubMed Web of Science ®Google Scholar
• Nemeikaite-Čeniene A, Sergediene E, Nivinskas H, Čenas N. Cytotoxicity of natural hydroxyanthraquinones: role of oxidative stress. Z Naturforsch C J Biosci. 2002;57(9-10):822–827.
   PubMedGoogle Scholar
• Zhang Q, Chen WW, Sun X, Qian D, Tang DD, Zhang LL, Li MY, Wang LY, Wu CJ, Peng W, et al. The versatile emodin: A natural easily acquired anthraquinone possesses promising anticancer properties against a variety of cancers. Int J Biol Sci. 2022;18(8):3498–3527.
   PubMed Web of Science ®Google Scholar
• Hsu SC, Chung JG. Anticancer potential of emodin. Biomedicine (Taipei)). 2012;2(3):108–116.
   PubMedGoogle Scholar
• Jia X, Yu F, Wang J, Iwanowycz S, Saaoud F, Wang Y, Hu J, Wang Q, Fan D. Emodin suppresses pulmonary metastasis of breast cancer cells accompanied with decreased macrophage recruitment and M2 polarization in the lungs. Breast Cancer Res Treat. 2014;148(2):291–302.
   PubMed Web of Science ®Google Scholar
• Kim M, Baek M, Kim DJ. Protein tyrosine signaling and its potential therapeutic implications in carcinogenesis. Curr. Pharm. Des. 2017;23(29):4226.
   PubMed Web of Science ®Google Scholar
• Huang L, Jiang S, Shi Y. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020). J Hematol Oncol. 2020;13(1):1–23.
   PubMed Web of Science ®Google Scholar
• Iqbal N, Iqbal N. Imatinib: A breakthrough of targeted therapy in cancer. Chemother Res Pract. 2014;2014:357027–357029.
   PubMedGoogle Scholar
• Li S. Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. Leuk Lymphoma. 2008;49(1):19–26.
   PubMed Web of Science ®Google Scholar
• Shayani S. Dasatinib, a multikinase inhibitor: therapy, safety, and appropriate management of adverse events. Ther Drug Monit. 2010;32(6):680–687.
   PubMed Web of Science ®Google Scholar
• Zhang M, Tian J, Wang R, Song M, Zhao R, Chen H, Liu K, Shim J-H, Zhu F, Dong Z, et al. Dasatinib inhibits lung cancer cell growth and patient derived tumor growth in mice by targeting LIMK1. Front Cell Dev Biol. 2020;8:556532.
   PubMed Web of Science ®Google Scholar
• Senapati J, Sasaki K, Issa GC, Lipton JH, Radich JP, Jabbour E, Kantarjian HM. Management of chronic myeloid leukemia in 2023 – common ground and common sense. Blood Cancer J. 2023;13(1):58.
   PubMed Web of Science ®Google Scholar
• Zvarych V, Stasevych M, Novikov V, Vovk M. Synthesis and study of antimicrobial activity of 2-dithiocarbamate-n-(9,10-dioxo-9,10-dihydroanthracenyl)acetamides. Biointerface Res. Appl. Chem. 2021;11(1):7725–7734.
   Web of Science ®Google Scholar
• Chiang J-H, Yang J-S, Ma C-Y, Yang M-D, Huang H-Y, Hsia T-C, Kuo H-M, Wu P-P, Lee T-H, Chung J-G, et al. Danthron, an anthraquinone derivative, induces DNA damage and caspase cascades-mediated apoptosis in SNU-1 human gastric cancer cells through mitochondrial permeability transition pores and Bax-triggered pathways. Chem Res Toxicol. 2011;24(1):20–29.
   PubMed Web of Science ®Google Scholar
• Malik MS, Alsantali RI, Jassas RS, Alsimaree AA, Syed R, Alsharif MA, Kalpana K, Morad M, Althagafi II, Ahmed SA, et al. Journey of anthraquinones as anticancer agents – a systematic review of recent literature. RSC Adv. 2021;11(57):35806–35827.
   PubMed Web of Science ®Google Scholar
• Podhorecka M, Skladanowski A, Bozko P. H2AX phosphorylation: its role in DNA damage response and cancer therapy. J Nucleic Acids. 2010;2010:1–9.
   Google Scholar
• Fouillaud M, Venkatachalam M, Girard-Valenciennes E, Caro Y, Dufossé L. Anthraquinones and derivatives from marine-derived fungi: structural diversity and selected biological activities. Mar Drugs. 2016;14(4):64.
   PubMed Web of Science ®Google Scholar
• The Human Protein Atlas. https://www.proteinatlas.org/. Accessed May 30, 2023.
   Google Scholar
• Maciejewska N, Olszewski M, Jurasz J, Baginski M, Stasevych M, Zvarych V, Folini M, Zaffaroni N. Teloxantron inhibits the processivity of telomerase with preferential DNA damage on telomeres. Cell Death Dis. 2022;13(11):1005.
   PubMed Web of Science ®Google Scholar
• Al-Otaibi JS, Teesdale Spittle P, El Gogary TM. Interaction of anthraquinone anti-cancer drugs with DNA:Experimental and computational quantum chemical study. J. Mol. Struct. 2017;1127:751–760.
   Web of Science ®Google Scholar
• Parsons SJ, Parsons JT. Src family kinases, key regulators of signal transduction. Oncogene. 2004;23(48):7906–7909.
   PubMed Web of Science ®Google Scholar
• Zhang S, Yu D. Targeting Src family kinases in anti-cancer therapies: turning promise into triumph. Trends Pharmacol Sci. 2012;33(3):122–128.
   PubMed Web of Science ®Google Scholar
• Sung NY, Kim MY, Cho JY. Scutellarein reduces inflammatory responses by inhibiting src kinase activity. Korean J Physiol Pharmacol. 2015;19(5):441–449.
   PubMed Web of Science ®Google Scholar
• Park JG, Kim SC, Kim YH, Yang WS, Kim Y, Hong S, Kim K-H, Yoo BC, Kim SH, Kim J-H, et al. Anti-inflammatory and antinociceptive activities of anthraquinone-2-carboxylic acid. Mediators Inflamm. 2016;2016:1903849.
   PubMed Web of Science ®Google Scholar
• Li E, Hristova K. Receptor tyrosine kinase transmembrane domains: Function, dimer structure and dimerization energetics. Cell Adh Migr. 2010;4(2):249–254.
   PubMed Web of Science ®Google Scholar
• Cohen P, Cross D, Jänne PA. Kinase drug discovery 20 years after imatinib: progress and future directions. Nat Rev Drug Discov. 2021;20(7):551–569.
   PubMed Web of Science ®Google Scholar
• Yang Y, Li S, Wang Y, Zhao Y, Li Q. Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. Signal Transduct. Target Ther. 2022;7(1):1–36.
   PubMed Web of Science ®Google Scholar
• Mohi MG, Boulton C, Gu T-L, Sternberg DW, Neuberg D, Griffin JD, Gilliland DG, Neel BG. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukaemia caused by oncogenic PTKs. Proc Natl Acad Sci U S A. 2004;101(9):3130–3135.
   PubMed Web of Science ®Google Scholar
• Discovery Studio Visualizer, v19. 1.0, BIOVIA. San Diego: Dassault Systems. 2018.
   Google Scholar
• Quiroga R, Villarreal MA. Vinardo. A scoring function based on Autodock Vina improves scoring, docking, and virtual screening. PloS One. 2016;11(5):e0155183.
   PubMed Web of Science ®Google Scholar